Skip to main content

Clinical trial EZH-202

A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

Cancers
Organ Tissus mous
Trial status Trial open for recruitment
Investigator
Trial type
Interventionnal with IMP
Phase Trial phase 2
Academic trial Non
Sponsor Epizyme
EudraCT Identifier 2015-002469-41
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02601950
Inclusion criteria after standard therapy
Last update